Regadenoson

{{DrugProjectFormSinglePage |authorTag=

Gerald Chi

|genericName=

Regadenoson

|aOrAn=

a

|drugClass=

|indication=

|hasBlackBoxWarning=

Yes

|adverseReactions=

|blackBoxWarningTitle= Title

|blackBoxWarningBody= ConditionName:

• Content

|fdaLIADAdult=

Condition1

• Dosing Information

• Dosage

Condition2

• Dosing Information

• Dosage

Condition3

• Dosing Information

• Dosage

Condition4

• Dosing Information

• Dosage

|offLabelAdultGuideSupport=

Condition1

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Regadenoson in adult patients.

|offLabelAdultNoGuideSupport=

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Regadenoson in adult patients.

|fdaLIADPed=

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding FDA-Labeled Use of Regadenoson in pediatric patients.

|offLabelPedGuideSupport=

Condition1

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Regadenoson in pediatric patients.

|offLabelPedNoGuideSupport=

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Regadenoson in pediatric patients.

|contraindications=

• Condition1

|warnings=

• Description

Precautions

• Description

|clinicalTrials=

There is limited information regarding Clinical Trial Experience of Regadenoson in the drug label.

Miscellaneous

|postmarketing=

There is limited information regarding Postmarketing Experience of Regadenoson in the drug label.

Miscellaneous

|drugInteractions=

• Drug

• Description

|useInPregnancyFDA=

• Pregnancy Category

|useInPregnancyAUS=

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Regadenoson in women who are pregnant.

|useInLaborDelivery= There is no FDA guidance on use of Regadenoson during labor and delivery.

|useInNursing= There is no FDA guidance on the use of Regadenoson with respect to nursing mothers.

|useInPed= There is no FDA guidance on the use of Regadenoson with respect to pediatric patients.

|useInGeri= There is no FDA guidance on the use of Regadenoson with respect to geriatric patients.

|useInGender= There is no FDA guidance on the use of Regadenoson with respect to specific gender populations.

|useInRace= There is no FDA guidance on the use of Regadenoson with respect to specific racial populations.

|useInRenalImpair= There is no FDA guidance on the use of Regadenoson in patients with renal impairment.

|useInHepaticImpair= There is no FDA guidance on the use of Regadenoson in patients with hepatic impairment.

|useInReproPotential= There is no FDA guidance on the use of Regadenoson in women of reproductive potentials and males.

|useInImmunocomp= There is no FDA guidance one the use of Regadenoson in patients who are immunocompromised.

|administration=

• Oral

• Intravenous

|monitoring=

There is limited information regarding Monitoring of Regadenoson in the drug label.

• Description

|IVCompat=

There is limited information regarding IV Compatibility of Regadenoson in the drug label.

|overdose=

Acute Overdose

Signs and Symptoms

• Description

Management

• Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Regadenoson in the drug label.

|drugBox=

{{Drugbox2 | Verifiedfields = changed | verifiedrevid = 413312613 | IUPAC_name = 2-{4-[(methylamino)carbonyl]- 1H-pyrazol-1-yl}adenosine | image = Regadenoson2.png | width = 300

| tradename = | Drugs.com = Multum Consumer Information | licence_US = Regadenoson | pregnancy_AU = | pregnancy_US = C | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Intravenous

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ^Y | CAS_number = 313348-27-5 | CAS_supplemental = 875148-45-1 | ATC_prefix = C01 | ATC_suffix = EB21 | ATC_supplemental = | PubChem = 219024 | DrugBank_Ref =  ^Y | DrugBank = | UNII_Ref =  ^N | UNII = 7AXV542LZ4 | KEGG_Ref =  ^Y | KEGG = D05711 | ChEMBL_Ref =  ^N | ChEMBL = 1201750

| chemical_formula = | C=15 | H=18 | N=8 | O=5 | molecular_weight = 390.354 g/mol | synonyms = 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- N-methylpyrazole-4-carboxamide }}

|mechAction=

|structure=

This image is provided by the National Library of Medicine.

|PD=

There is limited information regarding Pharmacodynamics of Regadenoson in the drug label.

|PK=

There is limited information regarding Pharmacokinetics of Regadenoson in the drug label.

|nonClinToxic=

There is limited information regarding Nonclinical Toxicology of Regadenoson in the drug label.

|clinicalStudies=

There is limited information regarding Clinical Studies of Regadenoson in the drug label.

|howSupplied=

|fdaPatientInfo=

There is limited information regarding Patient Counseling Information of Regadenoson in the drug label.

|alcohol=

• Alcohol-Regadenoson interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

|brandNames=

• Lexiscan®

|lookAlike=

• N/A

|drugShortage= }}

{{#subobject:

 |Page Name=Regadenoson
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Regadenoson
 |Label Name=Regadenoson11.png

}}

{{#subobject:

 |Label Page=Regadenoson
 |Label Name=Regadenoson11.png

}}